European Journal of Gastroenterology & Hepatology

Papers
(The H4-Index of European Journal of Gastroenterology & Hepatology is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Nonalcoholic fatty liver disease and risk of incident hypertension: a systematic review and meta-analysis46
Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management39
Gastrointestinal symptoms are associated with severity of coronavirus disease 2019: a systematic review and meta-analysis37
Neutrophil–lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysis35
Elevated platelet distribution width and red cell distribution width are associated with autoimmune liver diseases32
Malnutrition and sarcopenia are prevalent among inflammatory bowel disease patients with clinical remission31
Mean platelet volume and platelet to lymphocyte count ratio are associated with hepatitis B-related liver fibrosis29
Major gastrointestinal bleeding risk with direct oral anticoagulants: Does type and dose matter? – A systematic review and network meta-analysis28
Pre-hospitalization proton pump inhibitor use and clinical outcomes in COVID-1927
Clinical feasibility of panintestinal (or panenteric) capsule endoscopy: a systematic review25
Biliary stent migration: why, how, and what?24
Fibrosis-4 index and mortality in coronavirus disease 2019: a meta-analysis23
Risk factors and clinical characteristics of early-onset colorectal cancer vs. late-onset colorectal cancer: a case-case study23
Efficacy of omega-3-rich Camelina sativa on the metabolic and clinical markers in nonalcoholic fatty liver disease: a randomized, controlled trial22
Clinical features and predictive factors related to liver injury in SARS-CoV-2 Delta and Omicron variant-infected patients22
Clinical course and outcome among patients with acute pancreatitis and COVID-1921
Weight change and resolution of fatty liver in normal weight individuals with nonalcoholic fatty liver disease20
Long-term real-life efficacy and safety of infliximab and adalimumab in the treatment of inflammatory bowel diseases outpatients19
Effects of naringenin supplementation on cardiovascular risk factors in overweight/obese patients with nonalcoholic fatty liver disease: a pilot double-blind, placebo-controlled, randomized clinical t19
0.044320106506348